[PDF][PDF] The Children's Hospital of Philadelphia Research Institute Impact Factor Report, FY2008

HM Corneli, JJ Zorc, P Majahan, KN Shaw… - Rev Immunol, 2008 - academia.edu
Fishbein I, Alferiev I, Bakay M, Stachelek SJ, Sobolewski P, Lai M, Choi H, Chen IW, Levy
RJ. Local delivery of gene vectors from bare-metal stents by use of a biodegradable …

An academic centre for gene therapy research with clinical grade manufacturing capability

KB Islam, P Blomberg, K Wikström… - Annals of …, 1997 - Taylor & Francis
Huddinge University Hospital is a major teaching hospital affiliated with the Karolinska
Institute in Southern Stockholm. For the past few years several groups have been working …

Gene therapy made difficult

PA Kingston, AM Heagerty - Heart, 1999 - heart.bmj.com
Your editorial states “...(t) his inflammatory response is... generally observed using the sort of
adenoviral loads needed to achieve expression of the transgene”. Undoubtedly, many early …

[引用][C] VASCULAR IMPLANTS'NEW WAVE

S In - 1990 - nature.com
BETHESDA, Md.-One may not naturally associate implantable medical devices-such as
artificial heartswith biotechnology, or even biology. And vascular grafts typically consist of …

Application to vascular adventitia of a nonviral vector for TIMP-1 gene therapy to prevent intimal hyperplasia

QH Meng, W Jamal, SL Hart, JR McEwan - Human gene therapy, 2006 - liebertpub.com
Somatic gene transfer continues to have potential for the study and therapy of
cardiovascular disease. We have developed a modular, self-assembling, nonviral system …

[PDF][PDF] Activated az-Macroglobulin and Transforming Growth Factor-01 Induce a Synergistic Smooth Muscle Cell Proliferative Response

GA StoufferS, J LaMarreplI, SL GoniaspII, GK Owens - academia.edu
The role that soluble binding proteins might play in regulating transforming growth factor-81
(TGF-@ l)-induced growth of smooth muscle cells (SMC) is unknown. az-Macroglobulin …

Uso de um agente terapêutico e de um agente de intensificação de permeação intracelular

L Bender - 2023 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
50341876&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Growth of Human Blood Vessels in Severe Combined Immunodeficient Mice

PJ Polverini, JE Nör, MC Peters, DJ Mooney - John M. Walker, SERIES EDITOR - Springer
The development of strategies for the treatment of angiogenesis-dependent diseases has
been greatly aided by the development of in vivo models of angiogenesis (1). These …

[PDF][PDF] 1201 Gene Transfer to Vascular Tissues and Cell Therapies

A Hall - core.ac.uk
Conclusions: This study suggests that mean plaque size stabilizes at 4 weeks after carotid
injury with no further increase at later time points. Furthermore, there appears to be a time …

Periluminal Expression of a Secreted Transforming Growth Factor-? Type II Receptor Inhibits In-Stent Neointima Formation Following Adenovirus-Mediated Stent …

CE Appleby, P Ranjzad, PD Williams… - 1557 …, 2014 - escholar.manchester.ac.uk
Transforming growth factor-β1 (TGF-β1) has been shown unequivocally to enhance
neointima formation in carotid and ileo-femoral arteries. In our previous studies, however …